Cem Demirkiran

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Justin Harold, Stefania Bellone, Diego Manavella et al. · Gynecologic Oncology · 2022 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Blair McNamara, Cem Demirkiran, Tobias M.P. Hartwich et al. · Gynecologic Oncology · 2024 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

Dennis Mauricio, Stefania Bellone, Levent Mutlu et al. · Gynecologic Oncology · 2023 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Stefania Bellone, Kyungjo Jeong, Mari K. Halle et al. · Proceedings of the National Academy of Sciences · 2024 · 16 citations · Full text

Life Sciences, Genetics, Oncology +16

Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma

Blair McNamara, Michelle Greenman, Stefania Bellone et al. · Gynecologic Oncology · 2024 · 16 citations

Medicine, Oncology, Pharmacology +17